IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v21y2023i4d10.1007_s40258-022-00781-6.html
   My bibliography  Save this article

Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis

Author

Listed:
  • Pooyeh Graili

    (Quality HTA)

Abstract

Background and Objective Before listing by drug plans, new drugs that receive regulatory bodies’ approval are assessed by the Health Technology Assessment agencies, including the Canadian Agency for Drugs and Technologies in Health (CADTH). Considering the impact of CADTH recommendations on payers’ listing decisions, the growing number of high-cost drugs, and conditional listings, conditional recommendations have increasingly been of interest to the users of CADTH recommendations. This study aims to review the conditional reimbursement recommendations issued by CADTH and explores the reasons for those recommendations. Methods All final drug reimbursement recommendations posted on the CADTH website since 1 January, 2003 were reviewed. Recommendations were included if accepted for review by 1 May, 2021 and completed before 1 January, 2022. The complete records excluding ‘requests for advice’ were categorized into ‘reimburse,’ ‘do not reimburse,’ and ‘reimburse with criteria/condition(s)’. The identified variables were extracted and analyzed descriptively. Results Of the 889 submissions, 785 (88.6%) completed recommendations were considered relevant to the study purpose. Of 750 recommendations, excluding 35 (4.5%) ‘requests for advice,’ 500 (66.6%) were ‘reimburse with criteria/condition(s)’. ‘Clinical criteria’ at 481 (96.2%), ‘cost-effectiveness improvement to an acceptable level’ at 132 (26.4%), and ‘the treatment cost not to exceed the cost of the alternative option(s)’ at 118 (23.6%) were the most frequently reported conditions. The most frequent reasons for conditional reimbursement were ‘clinical benefit and economic evaluation’ at 304 (60.8%). Of conditional recommendations, 468 (93.6%) included more than one reason. Conclusions CADTH has facilitated patient access to innovative drugs even with limited evidence by conditional recommendations. The clinical criteria are the cornerstone of conditional recommendations. CADTH has developed the assessment process over time.

Suggested Citation

  • Pooyeh Graili, 2023. "Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis," Applied Health Economics and Health Policy, Springer, vol. 21(4), pages 673-681, July.
  • Handle: RePEc:spr:aphecp:v:21:y:2023:i:4:d:10.1007_s40258-022-00781-6
    DOI: 10.1007/s40258-022-00781-6
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40258-022-00781-6
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40258-022-00781-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:21:y:2023:i:4:d:10.1007_s40258-022-00781-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.